Dr. Alexander Guminski
Claim this profileRoyal North Shore Hospital
Studies Cancer
Studies Transitional Cell Carcinoma
4 reported clinical trials
16 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
HER2 positive
2Transitional Cell Carcinoma
Stage IV
Stage III
HER2 positive
Clinical Trials Alexander Guminski is currently running
Lorigerlimab + Docetaxel
for Prostate Cancer
This trial is testing whether adding lorigerlimab to standard treatments (docetaxel and prednisone) can slow down prostate cancer that has spread and is not responding to hormone therapy. Lorigerlimab helps the immune system fight cancer, while docetaxel kills cancer cells, and prednisone manages side effects. About 150 patients will participate, with some receiving the new combination and others receiving just the standard treatment.
Recruiting1 award Phase 2
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
More about Alexander Guminski
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alexander Guminski has experience with
- Cisplatin
- Etoposide
- Bleomycin Sulfate
- Filgrastim
- Pegfilgrastim
- Avelumab
Breakdown of trials Alexander Guminski has run
Cancer
Transitional Cell Carcinoma
Germ Cell Tumors
Urothelial Carcinoma
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Guminski specialize in?
Alexander Guminski focuses on Cancer and Transitional Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Alexander Guminski currently recruiting for clinical trials?
Yes, Alexander Guminski is currently recruiting for 2 clinical trials in St Leonards New South Wales. If you're interested in participating, you should apply.
Are there any treatments that Alexander Guminski has studied deeply?
Yes, Alexander Guminski has studied treatments such as Cisplatin, Etoposide, Bleomycin Sulfate.
What is the best way to schedule an appointment with Alexander Guminski?
Apply for one of the trials that Alexander Guminski is conducting.
What is the office address of Alexander Guminski?
The office of Alexander Guminski is located at: Royal North Shore Hospital, St Leonards, New South Wales 2065 Australia. This is the address for their practice at the Royal North Shore Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.